8-K: Nexalin Technology Announces $5.25 Million Public Offering Priced at $1.75 Per Share

Nexalin Technology has priced a public offering of 3,000,000 shares of common stock at $1.75 per share, expecting gross proceeds of approximately $5.25 million.

Summary

• Nexalin Technology, Inc. has entered into a placement agency agreement with Maxim Group LLC for a public offering of 3,000,000 shares of common stock.
• The offering is priced at $1.75 per share, before deducting placement agent fees and estimated offering expenses.
• The gross proceeds from the offering are expected to be approximately $5.25 million.
• Maxim Group LLC will receive a cash placement fee equal to 8.0% of the gross proceeds, plus reimbursement of up to $110,000 in expenses.
• The offering is expected to close on July 1, 2024, subject to customary closing conditions.
• The shares are being offered pursuant to a registration statement on Form S-1, which was declared effective on June 27, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company is successfully raising capital, but there are costs and risks associated with the offering.

Positives

• The company is successfully raising capital through a public offering.
• The offering is expected to provide approximately $5.25 million in gross proceeds.
• The offering has a clear timeline with an expected closing date of July 1, 2024.
• The company has secured a placement agent, Maxim Group LLC, to manage the offering.

Negatives

• The company will incur a cash placement fee of 8% of the gross proceeds.
• The company will also reimburse the placement agent for up to $110,000 in expenses.
• The offering is subject to customary closing conditions, which could potentially delay or prevent the closing.

Risks

• The offering may not close as expected if the required closing conditions are not met.
• The company is subject to risks and uncertainties that may cause actual results to differ materially from those projected.
• There is no guarantee of the successful placement of the shares.
• The company is relying on the placement agent to sell the shares on a reasonable best efforts basis.

Future Outlook

The company expects the offering to close on July 1, 2024, subject to customary closing conditions. The company also has a right of first refusal for the placement agent for 12 months for future offerings.

Management Comments

• The company has not provided any direct quotes in this document.

Industry Context

This public offering is a common method for companies to raise capital for operations and growth. The mental health industry is currently experiencing significant growth and investment, making this a potentially opportune time for Nexalin to raise funds.

Comparison to Industry Standards

• The 8% placement fee is within the typical range for similar offerings, although the specific percentage can vary based on the size and complexity of the deal.
• The expense reimbursement of up to $110,000 is also a standard practice in these types of transactions.
• The offering price of $1.75 per share is a key factor in determining the success of the offering and will be compared to the company's current trading price and the valuation of comparable companies.
• Comparable companies in the medical device and neurostimulation space include companies such as NeuroMetrix, Inc. and Neuronetics, Inc., which have also utilized public offerings to raise capital.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company will have additional capital to fund operations and growth.
• The company's financial position will be strengthened by the capital raise.
• The placement agent will receive fees and expense reimbursements for their services.

Next Steps

• The company will close the offering on July 1, 2024, subject to customary closing conditions.
• The company will file a final prospectus with the SEC on July 1, 2024.
• The company will use the proceeds from the offering for general corporate purposes.

Key Dates

Keywords

public offering, common stock, capital raise, placement agent, Maxim Group LLC, securities, shares, offering price, gross proceeds, registration statement